{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040985","form_type":"8-K","ticker":"PETV","cik":"0001512922","company_name":"PetVivo Holdings, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.321678+00:00","generated_at":"2026-06-08T03:30:06.257131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PetVivo Q2 FY2024 net loss widens to $3.66M; revenue down to $207K","bullets":["Revenue $207,366 vs $223,280 YoY, driven by lower clinic sales ($63,760 vs $105,016).","Net loss $3.66M ($0.28 EPS) vs $2.11M ($0.21 EPS) YoY; operating loss $2.94M.","Raised $2.35M from convertible note and registered direct offering in Q2.","Entered ATM sales agreement for up to $2.5M; raised additional $870K post-quarter.","Cash $55K at Sept 30, 2023; working capital $100K; clinical trial data for Spryng released."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040985","json":"https://secwatch.observer/filing/0001493152-23-040985.json","markdown":"https://secwatch.observer/filing/0001493152-23-040985.md","text":"https://secwatch.observer/filing/0001493152-23-040985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512922/000149315223040985/0001493152-23-040985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512922/000149315223040985/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:30:06.257131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42f99499d97532ff9c6e46405f16d62dfe5060b0","claim":"PetVivo Holdings, Inc. reported three months ended September 30, 2023 results: revenue $207,366, net income $3,661,153, EPS ($0.28) per share.","evidence_excerpt":"Second Quarter Financial Results For The Three Months Ended September 30, 2023 Compared to The Three Months Ended September 30, 2022 Total Revenues . Revenues were $207,366 and $223,280 for three months ended September 30, 2023 and 2022, respectively. Revenues in the three months ended September 30, 2023 consist of sales of our SpryngTM product to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512922/000149315223040985/0001493152-23-040985-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$207,366"},{"label":"Net income","value":"$3,661,153"},{"label":"EPS","value":"($0.28) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e1b9e8b1f583558f809172edcd84801a07ba3875","claim":"PetVivo Holdings, Inc. reported six months ended September 30, 2023 results: revenue $324,549, net income $6,554,730, EPS ($0.53) per share.","evidence_excerpt":"of shares outstanding was 12,987,641 and 10,053,463 for the three months ended September 30, 2023 and 2022, respectively. Year to Date Financial Results Revenues . Revenues were $324,549 for six the months ended September 30, 2023 compared to revenues of $281,454 in the six months ended September 30, 2022. Revenues in the six months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512922/000149315223040985/0001493152-23-040985-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended September 30, 2023"},{"label":"Revenue","value":"$324,549"},{"label":"Net income","value":"$6,554,730"},{"label":"EPS","value":"($0.53) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}